Lilly Increases Access to Clinical Trials Data
Eli Lilly and Company has announced it will begin sharing its clinical trial data with scientific researchers through www.clinicalstudydatarequest.com.
Eli Lilly and Company has announced it will begin sharing its clinical trial data with scientific researchers through www.clinicalstudydatarequest.com. The website, which houses data from several clinical trial sponsors, was created with support from PhRMA and EFPIA to increase access to and transparency of clinical trial results for researchers around the world.
The new portal, www.clinicalstudydatarequest.com, differs from previous Lilly data-sharing sites in that access will only be granted after approval of a research proposal by an independent scientific review panel. Lilly will not be involved in the decisions made by the independent scientific review panel.
The multi-sponsor portal will include Lilly-sponsored interventional clinical studies from approved medicines and indications in the U.S. and EU in the following categories:
- Phase 2, 3 or 4 studies used as part of a regulatory approval submitted to the U.S. Food and Drug Administration (FDA) on or after 1999;
- Phase 2, 3 or 4 global studies with a first patient visit after January 1, 2007; and
- Phase 2, 3 or 4 global or regional/local studies in indications approved in both the U.S. and EU with a first patient visit after January 1, 2014.
Lilly established www.lillyclinicalstudydata.com in January 2014 in an interim capacity. This will be replaced by the new site.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
